Emerging data suggest this peptide, a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to offer a notable step forward for obesity treatment. https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide